MXPA05008961A - Tratamiento de osteolisis excesiva con compuestos de indolinona. - Google Patents
Tratamiento de osteolisis excesiva con compuestos de indolinona.Info
- Publication number
- MXPA05008961A MXPA05008961A MXPA05008961A MXPA05008961A MXPA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A MX PA05008961 A MXPA05008961 A MX PA05008961A
- Authority
- MX
- Mexico
- Prior art keywords
- excessive
- osteolyisis
- treatment
- indolinone compounds
- compounds
- Prior art date
Links
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000003076 Osteolysis Diseases 0.000 abstract 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44886103P | 2003-02-24 | 2003-02-24 | |
| US10/780,917 US20040209937A1 (en) | 2003-02-24 | 2004-02-19 | Treatment of excessive osteolysis with indolinone compounds |
| PCT/US2004/005283 WO2004075775A2 (en) | 2003-02-24 | 2004-02-23 | Treatment of excessive osteolyisis with indolinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008961A true MXPA05008961A (es) | 2005-11-04 |
Family
ID=32930497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008961A MXPA05008961A (es) | 2003-02-24 | 2004-02-23 | Tratamiento de osteolisis excesiva con compuestos de indolinona. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040209937A1 (https=) |
| EP (1) | EP1599207A2 (https=) |
| JP (1) | JP2006518756A (https=) |
| KR (1) | KR20050113612A (https=) |
| AU (1) | AU2004216188A1 (https=) |
| BR (1) | BRPI0407793A (https=) |
| CA (1) | CA2516786A1 (https=) |
| MX (1) | MXPA05008961A (https=) |
| NZ (1) | NZ541825A (https=) |
| PL (1) | PL378762A1 (https=) |
| WO (1) | WO2004075775A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007141654A (ru) * | 2005-05-12 | 2009-05-20 | Пфайзер Инк. (US) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат |
| NZ566033A (en) * | 2005-09-19 | 2011-04-29 | Pfizer Prod Inc | Solid salt forms of a pyrrole substituted 2-indolinone |
| CN101379400A (zh) * | 2005-12-22 | 2009-03-04 | 诺华有限公司 | 可溶性人m-csf受体及其应用 |
| CN101367801B (zh) * | 2007-08-15 | 2011-01-12 | 上海恒瑞医药有限公司 | 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用 |
| AU2009265360A1 (en) * | 2008-07-02 | 2010-01-07 | Generics [Uk] Limited | Preparation of 3-pyrrole substituted 2-indolinone derivatives |
| CN102203085A (zh) * | 2008-07-10 | 2011-09-28 | 基因里克斯(英国)有限公司 | 用于制备苹果酸舒尼替尼晶体形式的新方法 |
| CN102239163A (zh) * | 2008-07-24 | 2011-11-09 | 特瓦制药工业有限公司 | 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法 |
| WO2010011834A2 (en) * | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US10898211B2 (en) | 2015-01-14 | 2021-01-26 | Crossroads Extremity Systems, Llc | Opening and closing wedge osteotomy guide and method |
| US10292713B2 (en) | 2015-01-28 | 2019-05-21 | First Ray, LLC | Freeform tri-planar osteotomy guide and method |
| US10376268B2 (en) | 2015-02-19 | 2019-08-13 | First Ray, LLC | Indexed tri-planar osteotomy guide and method |
| EP3470394B1 (en) * | 2016-06-09 | 2022-01-26 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| WO2021021640A1 (en) | 2019-07-26 | 2021-02-04 | Crossroads Extremity Systems, Llc | Bone repositioning guide system and procedure |
| US11779359B2 (en) | 2020-02-19 | 2023-10-10 | Crossroads Extremity Systems, Llc | Systems and methods for Lapidus repair of bunions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1255752T1 (sl) * | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2003031438A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
-
2004
- 2004-02-19 US US10/780,917 patent/US20040209937A1/en not_active Abandoned
- 2004-02-23 CA CA002516786A patent/CA2516786A1/en not_active Abandoned
- 2004-02-23 AU AU2004216188A patent/AU2004216188A1/en not_active Abandoned
- 2004-02-23 PL PL378762A patent/PL378762A1/pl not_active Application Discontinuation
- 2004-02-23 EP EP04713729A patent/EP1599207A2/en not_active Withdrawn
- 2004-02-23 BR BRPI0407793-8A patent/BRPI0407793A/pt not_active IP Right Cessation
- 2004-02-23 KR KR1020057015602A patent/KR20050113612A/ko not_active Withdrawn
- 2004-02-23 MX MXPA05008961A patent/MXPA05008961A/es unknown
- 2004-02-23 NZ NZ541825A patent/NZ541825A/en unknown
- 2004-02-23 WO PCT/US2004/005283 patent/WO2004075775A2/en not_active Ceased
- 2004-02-23 JP JP2006503797A patent/JP2006518756A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PL378762A1 (pl) | 2006-05-15 |
| EP1599207A2 (en) | 2005-11-30 |
| AU2004216188A1 (en) | 2004-09-10 |
| WO2004075775A2 (en) | 2004-09-10 |
| WO2004075775A3 (en) | 2005-04-14 |
| US20040209937A1 (en) | 2004-10-21 |
| KR20050113612A (ko) | 2005-12-02 |
| CA2516786A1 (en) | 2004-09-10 |
| NZ541825A (en) | 2008-11-28 |
| JP2006518756A (ja) | 2006-08-17 |
| BRPI0407793A (pt) | 2006-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05008961A (es) | Tratamiento de osteolisis excesiva con compuestos de indolinona. | |
| HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
| MY184101A (en) | Indoles | |
| SG10201811480WA (en) | Therapeutic compounds and compositions | |
| MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| MY147364A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| GB2430935A (en) | Tetrapeptide analogs | |
| MXPA05012680A (es) | Indoles novedosos de 3-azufre sustituidos. | |
| SG132672A1 (en) | 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
| EP2298304A3 (en) | Carboline derivatives useful in the treatment of cancer | |
| TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| TW200621230A (en) | Anti-tumor compounds | |
| UA95298C2 (ru) | Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств | |
| MX368173B (es) | Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho. | |
| GEP20084550B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| JO2886B1 (en) | Useful compounds in the inhibition of CHK1 | |
| TN2009000389A1 (en) | Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer | |
| WO2010027424A3 (en) | 9-substituted phenanthrene based tylophorine derivatives | |
| MX2007016469A (es) | Metodos de tratamiento utilizando ansamicinas de hidroquinona. | |
| TW200510386A (en) | Treatment of excessive osteolysis with indolinone compounds | |
| MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. | |
| UA96745C2 (en) | PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |